Pfizer Inc PFE

$28.89 +0.06 (0.21%)

Valuation

Market cap
164,326,784,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.66
P/E (forward)
9.68
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
21,598,700
Avg volume
33,090,832
Day's range
$28.62 – $28.99
Shares out
5,699,854,000
Stochastic %K
12%
Beta
0.31
Analysts
Hold
Price target
$30.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

TensorTheta Nov 14, 2:20 PM
$PFE sitting at a valuation that keeps splitting opinions. Bulls see a value play with the pipeline catching up, bears see a value trap until growth actually shows up. Multiple looks cheap on paper but the market's clearly pricing in more than just a number. Worth watching how sentiment shifts next
0 replies
Techdamentals Nov 14, 1:38 AM
The S&P 500 fell 0.40% to 7,561.67 on Friday, November 13, 2026 but finished the week up 2.5%. One number from $PFE's latest report: revenue was $16.583 billion in the third quarter of 2026, down 0.4% from $16.654 billion, while research and development spending rose 18% to $3.016 billion. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v3/PFE?ref=st
0 replies
Itsokman Nov 13, 9:13 PM
$PFE heh
0 replies
Parlandoconme Nov 13, 8:51 PM
$TOMZ ray ive been working all day and just popped on here. am i quoting you correctly when u said "major drop today" ? $STE $ABT wonder if any BSL-3s or 4s are spraying steramist? bet ray would know since he probably works for bioquell, that shit technology that ruins buildings in the attempt to clean them. Buy baby buy. somebody smart will buyout this company soon and it will rocket to the top. $PFE
0 replies
BiotechCatalystCalendar Nov 13, 8:25 PM
Weekly recap: what X wouldn't shut up about (week of Nov 9). $NVO: FDA ordered a rare eye-risk warning on all GLP-1 labels, Wegovy and Ozempic included. $PFE: Blackstone will fund up to $1.5B of Pfizer's monthly obesity shot berobenatide, still in testing. $LLY: Foundayo cut sleep apnea breathing pauses by up to 44% in Phase 3, and Lilly plans an FDA filing by year-end. Dates first. Hype later. Full week on the calendar, free: https://biotechcatalystcalendar.substack.com/p/issue-0-esmo-week-two-phase-3-oncology
0 replies
Makingmillions192 Nov 13, 6:51 PM
$LEXX Top 5 Lexaria DehydraTECH (DHT) GLP-1 breakthroughs: 1. 55% Fewer GI Side Effects: Phase 1b human trials cut GI issues by 55% and overall adverse events by 48% vs. Rybelsus. 2. Oral Delivery of Injectables: Proven human oral absorption for injectable-only liraglutide and tirzepatide. 3. SNAC-Free Semaglutide: Delivers oral semaglutide without Novo Nordisk’s patented SNAC enhancer. 4. 566% Brain Penetration: Boosts GLP-1 brain tissue concentration in animal models to better target satiety. 5. Faster, Fed-State Absorption: Faster peak levels, steadier glucose, and works with food. Should be at $10 min right now.. $4.60 per share in cash on hand 70+ patented IP on technology 3 active MTAs with big pharma evaluating their technology This stock is a ticking time bomb 📈 🔥 $LLY $VKTX $RANI $PFE
0 replies
GTA_Terminal Nov 13, 6:37 PM
$PFE options money leaned 55% to calls today on $2.0M in premium. On the tape, the shares fell 0.40% to $28.71. Calls were barely ahead at 55% of the premium.
0 replies
taxplanr Nov 13, 6:12 PM
Do you know what $MRNA $BNTX and $PFE really hate ... a non pharma treatment for Long COVID / vaccine look what they did to the stock since the announcement
0 replies